DelveInsight’s “Uveal Melanoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Uveal Melanoma, historical and forecasted epidemiology as well as the Uveal Melanoma market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Uveal Melanoma Overview
Melanoma is a type of skin cancer that develops when melanocytes (melanin-forming cells that give the skin its tan or brown color) start to grow out of control. It may commonly begin in a mole (skin melanoma), but eyes also have melanin-producing cells and can develop melanoma called ocular melanoma. Ocular melanoma most commonly develops in the cells of the middle layer of the eye (uvea). The uvea is composed of two parts: anterior (iris, ciliary body), and posterior (choroid). The anterior segment is separated from the posterior segment by the lens. Uvea is sandwiched between the outer layer (sclera) and the inner layer (retina).
Uveal Melanoma Epidemiology Insights
-
As per Ahmad et al. (2021), the overall age-standardized incidence rate (ASIR) of uveal melanoma in Germany was 6.41 person per million.
-
As per the study by Neumann et al. (2019), the incidence of uveal melanoma in Europe was found to be approximately 6 per million.
-
As per Gristani and Tura (2018), GNAQ mutation was noted in 45–49% of uveal melanoma biopsy samples, whereas GNA11 mutations have been noted in 31.9% of uveal melanoma samples.
-
According to Kaneko (2021), in a Japanese population, the incidence of uveal melanoma was found to be 0.25 per million.
Click here to learn more about the Uveal Melanoma Market Landscape
The Report Covers the Uveal Melanoma Epidemiology Segmented by:
-
Uveal Melanoma total incident cases
-
Uveal Melanoma total site-specific cases
-
Uveal Melanoma mutation-specific cases
-
Uveal Melanoma gene-specific treated cases
Uveal Melanoma Market Outlook
The Uveal Melanoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Uveal Melanoma market trends by analyzing the impact of current Uveal Melanoma therapies on the market, Uveal Melanoma unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Uveal Melanoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Uveal Melanoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Uveal Melanoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Uveal Melanoma Market
-
AstraZeneca
-
Novartis
-
Spectrum Pharmaceuticals
-
Merck Pharmaceuticals
-
Syndax Pharmaceuticals
And many others
Uveal Melanoma Therapies Covered and Analyzed in the Report:
-
Nivolumab
-
Dacarbazine
-
Selumetinib
-
BVD-523
-
Crizotinib
And many others
Learn more about the Key Companies and Emerging Therapies in the Uveal Melanoma Market
Table of Contents
-
Key Insights
-
Uveal Melanoma Introduction
-
Executive Summary of Uveal Melanoma
-
Disease Background and Overview
-
Epidemiology and patient population
-
Uveal Melanoma Emerging Therapies
-
Uveal Melanoma Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Uveal Melanoma Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services